- $6.44m
- -$30.08m
- $1.46m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.47 | 1.58 | 3.01 | 3.65 | 1.46 |
Cost of Revenue | |||||
Gross Profit | 1.21 | 0.771 | -0.63 | -5.08 | -13.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 30.3 | 28.1 | 66.2 | 102 | 89.2 |
Operating Profit | -28.8 | -26.5 | -63.2 | -98.8 | -87.8 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -28.7 | -26.6 | -65 | -98.7 | -87.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -28.7 | -26.6 | -65 | -98.7 | -87.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.7 | -26.6 | -65 | -98.7 | -87.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.7 | -26.6 | -65 | -98.7 | -87.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.17 | -4.79 | -11.7 | -0.627 | -13.8 |
Dividends per Share |